biOasis Technologies CEO Discusses Blood Brain Barrier Technology

Life Science Investing News

Midas Letter released a podcast interview with Rob Hutchison, CEO and chairman of biOasis Technologies Inc. (TSXV:BTI,OTCQX:BIOAF).

Midas Letter released a podcast interview with Rob Hutchison, CEO and chairman of biOasis Technologies Inc. (TSXV:BTI,OTCQX:BIOAF). In it, he discusses the company’s blood brain barrier technology, which “reliably delivers therapeutic compounds beyond the Blood Brain Barrier in mice so far.”

Hutchison states:

From our perspective, biOasis has over the last number of years … actually completed all of the ground-level experimental work that was necessary to advance this technology forward. It’s now been vetted by independent third parties, including industry itself — in other words, large pharma companies have evaluated the technology. So I think it provides an opportunity for immediate potential opportunities for shareholders and investors.

Click here to listen to the podcast at the Midas Letter site.

The Conversation (0)
MARKETS
COMMODITIES
CURRENCIES
×